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Introduction
Although cancer is still the leading cause of death 
among men and women worldwide, novel treat-
ment options are rapidly evolving. In order to 
improve treatment efficacy and minimize toxicity 
more specific targets have been identified. One of 
the most promising classes of targeted anticancer 
agents are the multikinase inhibitors (MKIs), 
including the tyrosine kinase inhibitors (TKIs). 
MKIs target specific tyrosine kinases within the 
tumor cell, where they play a key role in signal 
transduction, gene transcription, and DNA syn-
thesis.1 MKIs like osimertinib (for lung cancer) 
and cabozantinib (for kidney cancer) rapidly 
gained a place in standard of care treatment for 
multiple or new indications [e.g. regorafenib in 
primary liver cancer, after earlier approvals for 
gastrointestinal stromal tumor (GIST) and colo-
rectal cancer].
MKIs include both small molecule MKIs and 
large molecule MKIs. In this review we will solely 
focus on the small molecule MKIs. Small mole-
cule MKIs are administered orally, which gives 
them a clear advantage over conventional chemo-
therapy in terms of flexibility and patient conveni-
ence. Many MKIs show a narrow therapeutic 
window, whereas intra- and interpatient exposure 
is highly variable and multifactorial.2–4 Also fac-
tors like food, beverages, lifestyle, and pharmaco-
genetic polymorphisms may alter MKI 
bioavailability significantly.5 For example, as 
MKIs are predominately metabolized through 
phase I (e.g. CYP enzymes) or phase II enzymes 
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(e.g. UPD-glucuronyltransferases) or almost 
exclusively by phase II enzymes (e.g. in the case 
of afatinib), this makes them highly prone for 
drug–drug interactions (DDIs) involving drug 
metabolism.6 Moreover, since cancer patients 
often use multiple drugs concomitantly with their 
anticancer therapy, they are even more at risk for 
DDIs, compared with other patient groups.7
DDIs can be classified as pharmacodynamic or 
pharmacokinetic.8 Pharmacokinetic DDIs are 
defined as drug interactions regarding drug 
absorption, metabolism, distribution and elimi-
nation leading to altered plasma concentrations 
of a drug and possible unfavorable outcomes (e.g. 
increased toxicity and reduced treatment effi-
cacy). A pharmacodynamic interaction is the 
altered response in terms of toxicity and efficacy 
when two or more drugs affect similar molecular 
targets (e.g. membrane receptors). 
Pharmacodynamic DDIs can be additive, antago-
nistic or synergistic. For instance, epidermal 
growth factor receptor (EGFR) kinase inhibitors 
often show synergistic antitumor effects when 
combined with chemotherapy.9
Both the United States Food and Drug 
Administration (US FDA) and the European 
Medicines Agency (EMA) present guidelines 
for the interpretation of DDIs. However, 
because of discrepancies between recommenda-
tions, currently no clear general consensus for 
the management of DDIs is available. Therefore, 
the management of DDIs is challenging for cli-
nicians and the need for a general consensus is 
urgent.
This review article presents an overview of known 
pharmacokinetic DDIs regarding orally taken 
MKIs currently approved by the US FDA and 
EMA. Moreover, if possible, practical recom-
mendations are given for the management of 
DDIs during MKI therapy in clinical practice.
Methods
We conducted a search in PubMed and the Embase 
databases for English language studies published 
until 2 July 2018 for randomized clinical trials, 
observational studies, and reviews about US FDA 
and EMA-approved MKIs. We used the follow-
ing search MESH terms: ‘(Drug interactions) OR 
(Drug combination) AND (Drug name)’. In 
Embase, we used ‘clinical studies’, ‘humans’ and 
‘only in English’ as additional search limits. The 
search results were manually screened for rele-
vance. In addition, all MKI (US FDA and EMA) 
assessment reports were screened on the latest 
updates regarding DDIs in the scientific updates 
available at the EMA and US FDA website until 
2 July 2018. We included clinical drug–drug 
interaction studies in human and preclinical phar-
macokinetic studies investigating possible inter-
actions. We excluded studies which did not focus 
on pharmacokinetics or drug interactions. Clinical 
relevance of the interaction was scored on the 
basis of the US FDA-classification of the effect of 
drug interactions and the level of available evi-
dence as a ‘major’, ‘moderate’ or ‘minor’ interac-
tion. If there was no clinical pharmacokinetic 
study performed, the interaction potential was 
estimated on the basis of the inhibitory concen-




The absorption of MKIs can be significantly 
affected by altered intragastric pH. When intra-
gastric pH is elevated (e.g. due to proton pump 
inhibitors; PPIs), the MKI solubility, bioavaila-
bility, and eventually treatment efficacy may be 
significantly influenced (Figure 1).8,11–13 The 
impact of this ‘pH effect’ is highly variable per 
MKI and the clinical relevance of the DDI 
between MKIs and acid-suppressive agents (e.g. 
PPIs, H2-antagonists and antacids) must be 
assessed on an individual basis. A complete over-
view can be found in Table 1.14–35
Indecisive guidelines and the fact that 20–30% 
of all cancer patients have an indication for the 
use of acid-suppressive agents (ASAs) compli-
cate the management of this DDI.36 The general 
consensus is, if possible, to avoid the combina-
tion between MKIs and ASAs.37 However, if 
there is a distinct indication for an ASA (e.g. 
Barrett’s esophagus), a clear and practical advice 
to manage the DDI between MKIs and ASAs is 
essential to safeguard optimal MKI therapy. 
Based on the pharmacokinetics and pharmaco-
dynamics of both MKIs and ASAs, practical 
advice can be given for the management of the 
DDI between MKIs and PPIs, H2-antagonists 
(H2As) and antacids (see Figure 1 and Table 
1).13 This advice may be extrapolated to newly 
introduced MKIs with a known or suspected 
drug interaction with gastric suppressive agents 
KGAM Hussaarts, GDM Veerman et al.
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and thus with a great impact of the ‘pH effect’ as 
mentioned in Figure 1 and Table 1.
MKIs and PPIs. Since PPIs do not elevate intragas-
tric pH over the full 24 h-range, a window of rela-
tively low intragastric pH may be used to manage 
the DDI.38 If there is a hard indication for PPI use, 
MKIs should be taken at least 2 h before the PPI in 
the morning in a once-daily regimen, since MKIs 
can be absorbed completely within this win-
dow.13,38 Another possibility is to administer a 
MKI with an acidic beverage such as cola (pH = 
2.5) to manage the DDI, since the acidic beverage 
temporarily decreases stomach pH resulting in 
better MKI solubility and absorption.23 Further-
more, the influence of other acidic beverages [e.g. 
sprite (pH = 3.4) or orange juice (pH = 3.3)] on 
the absorption of MKIs has not been studied yet.
MKIs and H2-antagonists. Since most H2-antago-
nists show a short plasma half-life and are admin-
istered in a twice daily regimen (e.g. ranitidine), 
MKIs should be taken at least 2 h before or 10 h 
after the H2-antagonist intake according to US 
FDA and EMA guidelines.14,15
Management MKIs and antacids. Antacids are rel-
atively short-acting agents (e.g. magnesium 
hydroxide). MKIs should be administered at least 
2 h before, or 4 h after antacid intake, to manage 
this DDI.14,15
Drug transporters and intestinal enzymes
As mentioned previously, MKI absorption is a 
multifactorial process mediated and affected by 
passive diffusion, active transport through multi-
ple drug transporters, and intestinal metabolism.7 
The activity of these drug transporters and intes-
tinal enzymes may significantly influence MKI 
bioavailability.
Drug transporters are located throughout the 
body, especially in the gut, bile ducts, kidneys and 
the blood–brain barrier (Figure 2).39 The US FDA 
states: ‘membrane transporters can have clinically 
relevant effects on the pharmacokinetics and phar-
macodynamics of a drug in various organs and tis-
sues by controlling its absorption, distribution, and 
elimination. In contrast to drug metabolizing 
enzymes that are largely expressed in the liver and 
Figure 1. Working mechanism of the drug–drug interaction with an ASA: MKIs are arranged according to the 
clinical relevance and magnitude of the interaction in a descending order, with the most relevant interactions 
on top of the list. A PPI increases stomach pH after intake and thereby decreases absorption of MKIs and 
therefore bioavailability of MKIs.
ASA, acid-suppressive agent; DDI, drug–drug interaction; MKI, multikinase.
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small intestines’.10 Therefore, the effect of a DDI 
considering drug transporters may be of greater 
clinical relevance then is assumed so far.
Furthermore, efflux drug transporters like 
P-glycoprotein, or P-gp (ATP-binding cassette 
subfamily B member 1, ABCB1) and also breast 
cancer resistance protein (BCRP; ATP-binding 
cassette subfamily G member 2, ABCG2) may play 
a crucial role in drug absorption and enterohepatic 
recirculation. Enterohepatic recirculation is the 
process in which foreign chemicals are absorbed 
Figure 2. Distribution of drug transporters and metabolizing enzymes: A complete overview of all the drug 
transporters and metabolizing phase I and phase II enzymes are presented in this figure for the main organs 
involved in the pharmacokinetics of drugs.
BCRP, breast cancer resistance protein (ABCG2); CYP, cytochrome P450 iso-enzyme, MATE, multi-antimicrobial extrusion 
protein; MRP, multidrug resistance associated protein; OAT, organic anion transporters; OATP, organic anion transporting 
peptides; OCT, organic cation transporters; P-gp, P-glycoprotein (ABCB1); UGT, UDP-glucuronosyltransferase.
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into the portal blood stream and metabolized by 
hepatocytes, secreted into the bile and eventually 
are reabsorbed after secretion of bile in the gut 
lumen.40 In this multi-step process drug transport-
ers like P-gp and BCRP play a significant role. 
Other drug efflux transporters that may influence 
MKI bioavailability are the multidrug resistance 
protein subfamily (ATP-binding cassette subfamily 
C member 1 to 12, ABCC1 to 12, like MRP1) and 
the multi-antimicrobial extrusion protein (MATE), 
while several uptake transporters may be involved 
as well [e.g. organic anion transporting peptides 
(OATPs), organic anion transporters (OATs), and 
organic cation transporters (OCTs), see Figure 2].
Many drugs are known P-gp inhibitors (e.g. vera-
pamil) or act as a strong P-gp-inducer (e.g. 
rifampicin). Drugs like cyclosporine, an inhibitor of 
several OATPs (e.g. OATP1B1 and BCRP) and 
cimetidine (OCT2 inhibitor) may influence other 
drug transporters as well. 41 For example, nint-
edanib showed a decrease in both area under the 
curve (AUC) and maximum concentration (Cmax) 
when co-administered with rifampicin. Since nint-
edanib is almost exclusively metabolized by phase 
II enzymes, this effect on AUC and Cmax is most 
likely due to P-gp induction.42 In general the use of 
strong P-gp or BCRP inhibitors or inducers is dis-
couraged when MKIs are substrates for these trans-
porters. Furthermore, many MKIs show inhibition 
of several drug transporters by themselves 
(Table 2).14,15,18,21,35,41,43–59 When a MKI acts like 
an inhibitor of these transporters and is co-admin-
istered with drug transporter substrates with a nar-
row therapeutic window (e.g. digoxin), close 
monitoring of side effects (e.g. severe arrhythmia 
for digoxin) is warranted. For some MKIs the clini-
cal relevance of DDIs regarding drug transporters 
is negligible and the combination with inhibitory or 
inducing compounds is considered to be well toler-
ated (e.g. bosutinib).14,15
In contrast with the above mentioned unwanted 
adverse effects, mostly found in preclinical stud-
ies, DDIs concerning drug transporters and MKIs 
may also be used in a beneficial way. For exam-
ple, MKIs may potentially increase chemotherapy 
concentrations through P-gp or BCRP inhibition 
(e.g. increased paclitaxel plasma concentration 
resulting from P-gp inhibition by nilotinib or 
increased nilotinib concentrations as a result of 
P-gp inhibition by imatinib).60,61
In conclusion, we found only a limited number of 
clinical studies, which investigated the effects of 
inhibition or induction of drug transporters by 
MKIs, since this is a relatively novel field of DDI 
research. Combinations between strong drug 
transporter inhibitory or inducing compounds 
should be avoided for most MKIs as mentioned 
in Table 2.
Intestinal metabolism
Another important factor in drug absorption is 
intestinal metabolism. Many MKIs are metabo-
lized in the gut wall through intestinal CYP3A4, 
which is often in close proximity of drug transport-
ers, such as P-gp. When a MKI is given concomi-
tantly with an intestinal CYP3A4 inducer (e.g. 
rifampicin) or inhibitor (e.g. grapefruit juice) this 
may significantly change MKI bioavailability.62 
However, in contrast, Van Erp and colleagues 
failed to show a significant increase in sunitinib 
exposure, when co-administered with grapefruit 
juice.63 Moreover, since many MKIs undergo 
extensive first-pass metabolism and are thus 
dependent of both intestinal and hepatic metabo-
lism, it is difficult to determine whether intestinal 
metabolism or hepatic metabolism is the main 
contributor to an altered drug bioavailability.
Metabolism
In the liver, MKIs are predominately metabolized 
by CYP enzymes into either active or inactive 
metabolites. For some MKIs, like nintedanib, 
phase II metabolism through UDP-
glycosyltransferases (UGTs), glutathione 
S-transferases and sulfotransferases (SULTs) is 
dominant in their metabolism.6,64,65 Inhibition or 
induction of these phase I and II enzymes by co-
administered medication may lead to either 
(severe) toxicity or loss of effective MKI therapy, 
respectively.
As DDIs with strong CYP3A4 inhibitors and 
inducers (e.g. ketoconazole and rifampicin, respec-
tively) play a significant role in MKI therapy, they 
are usually well described and clear recommenda-
tions for the management of these DDIs are pre-
sented in the assessment report. There are many 
(strong) inducers or inhibitors of CYP enzymes for 
which a complete overview can be found at the 
FDA and EMA websites.41,66 Moreover, some 
MKIs (e.g. imatinib, pazopanib) also displayed 
inhibitory or inducing activity by themselves.67–70 
The general advice is to avoid concomitant admin-
istration with strong inhibitors or inducers of CYP 
enzymes. If this is not possible, a MKI dose 
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adjustment, based on the advice given in the 
assessment report is recommended. For strong 
inducers a gradual dose escalation of the prescribed 
dose is advised with close monitoring of MKI-
specific side effects. For an overview of clinically 
relevant DDIs and for practical recommendations 
see Table 3.14,15,41,43,44,67-69,71–93
Interactions with novel MKIs
In the last decade there has been a significant 
increase in the development of and treatment 
with MKIs resulting in more than a doubling of 
registered MKIs in the past 5 years. Earlier, we 
described the DDIs with MKIs which were 
approved before 1 August 2013.6 Here, we give 
an extensive overview of the DDI potential and 
management of the novel MKIs, which have been 
approved after August 2013. A complete over-
view including all (new and older) MKIs is pre-
sented in Tables 1–3.
Afatinib. Afatinib is used in the treatment of non-
small cell lung cancer (NSCLC). It is a substrate 
of P-gp and BCRP and is mainly metabolized 
through enzyme-catalyzed Michael adduct for-
mation (phase II) and only in a minor extent to 
phase I enzymes like CYP3A4 and FMO 
(2%).14,15 Concomitant administration with rito-
navir (a P-gp inhibitor) showed a 48% increase in 
AUC and 39% increase in Cmax.43 Treatment with 
a potent P-gp inducer (rifampicin) prior to single-
dose afatinib showed a moderate effect on both 
afatinib AUC and Cmax (34% and 22% decrease 
respectively).43 When afatinib is administered 
with strong P-gp and BCRP inhibitors, staggered 
dosing may be used, preferably 6 h or 12 h apart 
from afatinib intake. When afatinib is adminis-
tered with strong P-gp inducers the dose may be 
increased with 10 mg with close monitoring of 
side effects. Administration with strong CYP 
inducers or inhibitors is considered safe, since no 
CYP enzymes are involved in afatinib metabo-
lism. Furthermore in vitro studies showed afatinib 
itself to be an inhibitor of P-gp and BCRP, so 
close monitoring of side effects when adminis-
tered with substrates for these transporters with a 
narrow therapeutic window is recommended.14,15
Alectinib. The anaplastic lymphoma kinase 
(ALK) inhibitor alectinib is used in the treatment 
of metastatic lung cancer. Alectinib as well as its 
M4 metabolite are considered equally active. 
Alectinib is primary metabolized by CYP3A4.14,15 
Co-administration with the strong CYP3A4 
inhibitor posaconazole resulted in a 75% increase 
of AUC, while co-administration with rifampicin 
led to a 73% decrease in alectinib AUC.44 Since 
alectinib and M4 are equally active, a dose modi-
fication is not necessary (unless patients experi-
ence a significant increase in toxicity) when 
alectinib is administered with strong inhibitors or 
inducers of CYP3A4. Since alectinib is a P-gp 
and BCRP inhibitor, close monitoring of side 
effects of these substrates is recommended, espe-
cially for drugs with a narrow therapeutic window 
(e.g. digoxin).
Bosutinib. Bosutinib is used in the treatment of 
chronic myeloid leukemia (CML). Although 
bosutinib is a P-gp substrate and inhibitor, DDIs 
are not likely to appear, since clinical studies 
demonstrated no significant effect on dabigatran 
(P-gp substrate) or bosutinib (when administered 
with the P-gp inhibitor lansoprazole) pharmaco-
kinetics.18,45 Therefore no bosutinib dose reduc-
tions are necessary, when administered with 
strong P-gp inducers or inhibitors. Bosutinib is 
mainly metabolized through CYP3A4 and co-
administration with the strong inhibitor ketocon-
azole resulted in 420% increase in Cmax and 760% 
increase in AUC.74 Administration with rifampi-
cin showed a significant 86% reduction in Cmax 
and a 92% decrease in AUC of bosutinib. Admin-
istration with the moderate inhibitor aprepitant 
also showed an increase in AUC and Cmax.73 In 
conclusion; strong inhibitors or inducers of 
CYP3A4 must be avoided or a gradual 20% dose 
reduction should be applied, when co-adminis-
tered with strong inhibitors of CYP3A4. Increas-
ing the bosutinib dose is not useful, when 
co-administered with strong CYP3A4 inducers, 
since a maximal tolerated bosutinib dose of 
600 mg is often not sufficient to compensate for 
the relatively large loss of exposure.14,15
Cabozantinib. Cabozantinib is used in the treat-
ment of medullary thyroid carcinoma and renal 
cell carcinoma (RCC). Since cabozantinib is a 
P-gp and BCRP inhibitor, close monitoring of side 
effects of substrates with a narrow therapeutic win-
dow is recommended when co-administered with 
cabozantinib.14,15 A study with ketoconazole and 
rifampicin showed a significant change in AUC 
(38% increase and 77% decrease, respectively).75 
There was no significant effect of cabozantinib on 
rosiglitazone (a CYP2C8 substrate) plasma phar-
macokinetics, indicating no inhibitory effect on 
CYP2C8 in contrast to the in vitro data.75 The 
product label recommends minimizing the risk of a 
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DDI by avoiding co-administration with strong 
inducers or inhibitors of CYP3A4. If necessary, a 
dose adjustment (decrease or increase) of 20 mg 
following a step-by-step approach may be 
warranted.
Ceritinib. Ceritinib is used in the treatment of 
ALK-positive NSCLC. Ceritinib is a substrate 
and inhibitor for P-gp. Furthermore, ceritinib is 
mainly metabolized by CYP3A4. Treatment with 
ketoconazole resulted in 190% and 20% increase 
in ceritinib AUC and Cmax, respectively.14,15 Co-
administration with rifampicin showed a 70% and 
44% decrease in AUC and Cmax, respectively.14,15 
If concomitant administration with strong inhibi-
tors of CYP3A4 is unavoidable a dose reduction 
by one third of the initial dose is necessary 
(rounded to units of 150 mg). For strong CYP3A4 
inducers gradual dose escalation is possible with 
close monitoring of MKI-specific side effects.
Cobimetinib. Cobimetinib is a BRAF inhibitor 
used in the treatment of melanoma. It is a sub-
strate for P-gp and inhibits BCRP, OATP1B1, 
OATP1B3, and OCT1.14,15 Therefore, close 
monitoring of side effects is warranted when cobi-
metinib is administered with BCRP (e.g. rosuvas-
tatin), OATP1B1, OATP1B3 (e.g. atorvastatin) 
or OCT1 substrates (metformin) with a narrow 
therapeutic window. Cobimetinib is primarily 
metabolized by CYP3A4 and UGT2B7. When 
co-administered with itraconazole 570% and 
220% increase in AUC and Cmax was seen, respec-
tively.14,15 A physiologically based pharmacoki-
netic (PBPK) model demonstrated rifampicin to 
decrease cobimetinib AUC by 83% and Cmax by 
63%.76 So, the co-administration with strong 
inhibitors or inducers of CYP3A4 and P-gp must 
be avoided. However, rabeprazole (a P-gp inhibi-
tor) showed no effects on the pharmacokinetics of 
cobimetinib.21 If concomitant use of cobimetinib 
and strong CYP3A4 inhibitors is unavoidable, the 
cobimetinib dose should be decreased with 20 mg 
(33%) following a step-by-step approach. Fur-
thermore, since cobimetinib is a CYP1A2 inhibi-
tor, concomitant use with CYP1A2 substrates 
(e.g. haloperidol) may lead to altered plasma con-
centrations of these substrates.14,15
Dabrafenib. Dabrafenib is a BRAF inhibitor used 
in the treatment of advanced melanoma and 
NSCLC. Dabrafenib was shown to be a substrate 
for P-gp and BCRP. Since the bioavailability of 
dabrafenib is high (95%), only limited pharmaco-
kinetic effects can be expected with inhibitors and 
inducers of these drug transporters. Dabrafenib is 
metabolized by both CYP3A4 (24%) and 
CYP2C8 (67%). Administration of dabrafenib 
with ketoconazole, gemfibrozil (a CYP2C8 inhibi-
tor), and rifampicin showed significant changes in 
AUC, however these effects were mostly relatively 
small.14,15 Furthermore, dabrafenib is known to 
auto-induce CYP3A4 mediated metabolism.14,15 
In conclusion, concomitant administration with 
strong CYP3A4 and CYP2C8 inhibitors or induc-
ers must be avoided. Furthermore, a study with 
warfarin showed a 37% and 33% decrease in AUC 
and an 18% and 19% decrease in Cmax for S-war-
farin (a CYP2C9 substrate) and R-warfarin (a 
CYP3A4/CYP1A2 substrate), respectively.78 
Therefore, dabrafenib is characterized as a moder-
ate CYP3A4 inducer and a weak CYP2C9 inducer 
and as a result concomitant use of substrates for 
these enzymes must be avoided.78
Ibrutinib. Ibrutinib is used as treatment for 
chronic lymphatic leukemia (CLL) and mantle 
cell lymphoma. Ibrutinib is an inhibitor of P-gp 
and BCRP.14,15 Ibrutinib is mainly metabolized 
by CYP3A4. Ketoconazole gave 2800% and 
2300% increase in Cmax and AUC respec-
tively.14,15,51 Furthermore concomitant adminis-
tration with rifampicin showed 92% and 90% 
decrease in Cmax and AUC respectively.14,15 
Administration with a moderate inhibitor of 
CYP3A4 (e.g. erythromycin) led to 240% and 
200% increase in Cmax and AUC respec-
tively.14,15,82 Overall concomitant administration 
with strong CYP3A4 inhibitors or inducers must 
be avoided. If ibrutinib is administered with mod-
erate and strong CYP3A4 inhibitors the ibrutinib 
dose should be reduced to 280 mg and 140 mg 
respectively. When ibrutinib is administered with 
substrates of P-gp and BCRP monitoring of side 
effects of these substrates is warranted. When tox-
icity appears the dose of these substrates may be 
decreased.
Lenvatinib. Lenvatinib is used in the treatment of 
RCC and advanced thyroid carcinoma. It was 
shown to be a MDR1 substrate, a P-gp and 
BCRP substrate and inhibitor and an OATP1B3 
inhibitor in vitro.14,15 When lenvatinib is adminis-
tered with ketoconazole or rifampicin, only mar-
ginal changes in AUC and Cmax were observed.54,55 
Since lenvatinib is mainly metabolized through 
several phase II mechanisms (e.g. aldehyde oxi-
dase and glutathione conjugation) into less active 
metabolites and only for a small part by CYP3A4, 
these changes were most likely due to an 
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interaction with P-gp.14,15 Lenvatinib has an 
overall low DDI potential and dose modifications 
are currently not considered necessary.
Nintedanib. Nintedanib is used in the treatment 
of NSCLC. It is a substrate and weak inhibitor of 
P-gp.14,15,94 When nintedanib is administered with 
a strong P-gp inhibitor, a 100 mg (25%) step-wise 
daily dose reduction must be considered with 
close monitoring of side effects. Use of strong 
P-gp inducers must be avoided, since nintedanib 
plasma concentrations may decrease. Nintedanib 
is mainly metabolized due to hydrolysis by ester-
ases and glucuronidated by UGT with only a 
minor involvement of CYP enzymes (CYP3A4; 
5%).14,15 Administration with ketoconazole 
resulted in 61% and 83% increase in AUC and 
Cmax respectively and administration with rifam-
picin demonstrated a decrease in AUC of 50% 
and 60% of Cmax respectively.42 These differences 
were probably due to a DDI with P-gp. Therefore, 
concomitant administration with strong inhibi-
tors or inducers of CYP3A4 is considered safe.
Osimertinib. Osimertinib is used in the treatment 
of NSCLC.14,15 Osimertinib is a substrate and 
inhibitor for P-gp and BCRP.14,15 A study with 
rosuvastatin (a sensitive BCRP substrate) showed 
an increase in AUC and Cmax of 35% and 72% of 
rosuvastatin respectively.87 Osimertinib is mainly 
metabolized by CYP3A4 and CYP3A5, but only 
rifampicin resulted in a significant change in both 
AUC and Cmax in contrast to itraconazole.86 A 
study with simvastatin (a CYP3A4 substrate) 
resulted in a slight decrease in AUC and Cmax of 
simvastatin of 9% and 23%, but these changes are 
not considered to be of clinical significance.87 In 
conclusion only strong CYP3A4 inducers must 
be used with caution and close monitoring of side 
effects of osimertinib is warranted.
Ponatinib. Ponatinib is used in the treatment of 
CML and Acute lymphatic leukemia (ALL). Pona-
tinib is a substrate and inhibitor of P-gp and 
BCRP.14,15 Therefore, concomitant use of pona-
tinib with strong inhibitors or inducers of these 
transporters should be avoided. Ponatinib is mainly 
metabolized into nonactive metabolites by CYP3A4 
and to a lesser extent by CYP2D6, CYP2C8 and 
CYP3A5.14,15 A study with concomitant ketocon-
azole administration showed an increase in Cmax of 
47% and 78% in AUC of ponatinib.88 Multiple 
dosing of rifampicin demonstrated a decrease in 
AUC and Cmax of 42% and 62% respectively.89 As 
a consequence, concomitant administration with 
inhibitors of CYP3A4 and P-gp should be avoided 
or a dose reduction to 30 mg should be applied 
when administered concomitantly. Moreover, the 
use of strong CYP3A4 or P-gp inducers must be 
avoided or duration must be minimized, since 
ponatinib exposure may change.
Tivozanib. Tivozanib is used in the treatment of 
RCC. Tivozanib is an inhibitor of BCRP and is 
metabolized by multiple liver enzymes, including 
CYP3A4, CYP1A1 and several UGT1A enzymes 
(e.g. UGT1A1, UGT1A3 and UGT1A7).14,15 A 
study with rifampicin showed a 52% decrease in 
tivozanib AUC. Therefore, the administration 
with strong CYP3A4 inducers should be avoided. 
A dose escalation is not necessary since the effect 
on tivozanib exposure is relatively small. Keto-
conazole did not result in significant changes in 
tivozanib exposure.14,15,91 Administration with 
strong CYP3A4 inhibitors is therefore considered 
safe. Furthermore, the concomitant administra-
tion with strong UGT inhibitors or inducers (e.g. 
probenecid or ibuprofen) should be avoided since 
tivozanib plasma concentrations potentially may 
change.
Trametinib. Trametinib is used in the treatment 
of melanoma and NSCLC. It is a known inhibitor 
of P-gp, BCRP, OAT1, OAT3, OATP1B1, 
OATP1B3, OAT2B1, OCT2 and MATE1 and a 
substrate for P-gp.14,15 As a result, the use of 
strong inhibitors or inducers of P-gp (e.g. keto-
conazole) must be avoided. Trametinib is metab-
olized through deacetylation, oxidation and 
glucuronidation pathways.14,15 No drug interac-
tion studies are available to date, however since 
trametinib is not dependent on CYP isoenzymes, 
no DDIs with CYPs are to be expected.
DDI studies with longer available MKIs
In recent years several new studies have been 
published that investigated DDIs with longer 
available MKIs. Most of these studies are listed in 
Tables 1–3. There are only a few clinical DDI 
studies concerning drug transporters, since most 
studies mainly focus on CYP interactions. A 
phase I study investigated the combination of 
gefitinib and irinotecan and found an increase in 
SN-38 (the active irinotecan metabolite) and 
irinotecan plasma exposure, attributed to an 
enhanced BCRP activity in the gut.50 Moreover, 
in patients using sorafenib with rifampicin, the 
concentration of the metabolite sorafenib- 
glucuronide increased, suggesting inhibition of 
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OATP1B1 by rifampicin and confirms sorafenib 
as an OATP1B1 substrate.57
Several new studies investigated possible DDIs 
regarding drug metabolism. For a complete over-
view see Table 3. For example: imatinib co-
administration caused a 26% increase in 
cyclosporine (CYP3A4 and CYP2C8 substrate) 
plasma levels, explained by CYP3A4 inhibition 
by imatinib.69 In addition, lapatinib and pazo-
panib demonstrated an increase of 23% and 26% 
in paclitaxel AUC respectively, suggesting inhibi-
tion of CYP2C8 by these MKIs.83,95 Furthermore, 
regorafenib significantly increased the exposure 
to irinotecan and its active metabolite SN-38 due 
to UGT1A1 inhibition.96,97
Although most MKIs are metabolized through 
CYP enzymes it becomes more apparent that 
MKI metabolism is multifactorial and the inhibi-
tion and induction of other pathways (such as 
drug transporters) may also significantly influ-
ence MKI exposure. More research is needed to 
fully assess the DDI potential of these new path-
ways and their clinical relevance.
Discussion
Many MKIs have a narrow therapeutic window, 
with a clear relation between exposure and 
response on one hand and toxicity on the other.98 
For example, sunitinib and pazopanib show 
increasing severe toxicity with raising plasma con-
centration, leading to dose reductions and dis-
continuation of treatment in many patients.99,100 
Meanwhile, a threshold for efficacy for these 
drugs is seen.98–100 Therefore, it is important to 
provide the right dose for the individual patient, 
in order to optimize treatment efficacy and mini-
mize toxicity. To accomplish this, there is a shift-
ing paradigm towards personalized dosing in 
oncology practice.5 Along with other factors, 
DDIs are key factors influencing MKI exposure 
and subsequent clinical outcome. In addition, 
cancer patients are at greater risk for DDIs.7 
Therefore, a structured medication review for 
clinically relevant DDIs should take place on a 
regular basis.
To create a solid base for medication review, 
more DDI studies are strongly needed and results 
should be weighed on their clinical relevance. 
Specific and practical guidelines must be devel-
oped to guide clinicians and pharmacists in the 
management of DDIs in clinical practice. A 
practical way to reach this goal is by establishing 
clinical expert groups for consensus-based evalu-
ation of clinical significance and management of 
the DDIs.101
ASAs may strongly decrease MKI bioavailability. 
Since there is no clear general consensus on the 
management of this DDI we presented a practical 
advice for all ASAs. However, another problem is 
that there is no standard design for clinical DDI 
research with ASAs. Ideally, drug exposure 
should be compared in a crossover design between 
MKI monotherapy and during co-administration 
of the strongest ASA [e.g. the PPI esomeprazole 
(40 mg)] 3 h prior to MKI administration, since 
maximum intragastric pH elevating effect of this 
PPI is reached after this time period.38 In that 
case, when no effects are seen, a DDI between 
MKIs and PPIs can be ruled out. When a signifi-
cant DDI with H2-antagonists and antacids is 
expected, a corresponding treatment arm may be 
added. A more standardized study design of these 
ASA-DDI studies may provide a solid basis for 
practical management of this DDI, since study 
results could more easily be interpreted and com-
pared between different MKIs.
Drug transporters are located throughout the 
body and thus potentially influence pharmacoki-
netics on multiple levels.39 To date, insufficient 
attention has been given to the clinical relevance 
of these DDIs concerning drug transporters. 
Unfortunately, there is a lack of clinical studies 
investigating this type of DDI. Furthermore, 
many registration studies use ketoconazole or 
rifampicin as an inhibitor or inducer of CYP3A4, 
but these drugs are also strong inhibitors or 
inducers of P-gp. As a result, the P-gp effect may 
be underestimated or overestimated in the assess-
ment reports. More research is needed to fully 
assess the DDI potential concerning drug 
transporters.
In contrast, DDIs with drug transporters may 
also be used for beneficial purposes. For instance, 
inhibition of certain drug transporters (e.g. P-gp) 
in the blood–brain barrier might theoretically lead 
to altered blood–brain barrier penetration, which 
may result in better brain (metastasis) penetra-
tion of a MKI, for example, osimertinib.102 In 
addition, Zimmerman and colleagues demon-
strated a protective effect on hand-foot skin reac-
tion in mice, a frequently seen side effect of 
sorafenib, when sorafenib was concomitantly 
taken with the OAT6 inhibitor probenecid.103 
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Furthermore erlotinib may reduce cisplatin toxic-
ity (e.g. nephrotoxicity and ototoxicity) through 
OCT2 inhibition.48 Such potentially useful appli-
cations of DDIs between MKIs and drug trans-
porters need to be further explored, and may in 
the future result in more effective MKI therapy.
In current DDI research there is a trend towards 
a model-based DDI prediction, like the PBPK-
models.104,105 PBPK-models are multi-compart-
mental (often represented as single organs or 
tissues) models which use (in vitro) pharmacoki-
netic data and human physiologically-dependent 
system parameters to predict DDIs with a math-
ematical model.106 A disadvantage of PBPK mod-
eling is the lack of sufficient in vivo data that adds 
to the uncertainty in the predictions of the PBPK 
model. Also, the lack of knowledge regarding 
multifactorial physiologic changes in, for instance, 
enzyme and transporter expression and activity 
might be a possible confounding factor. Despite 
the evident benefits of PBPK modeling in current 
DDI research, confirmatory evidence from clini-
cal trials in humans is needed to assess a good 
predicting model.105
Another novel approach in oncology in managing 
DDIs is therapeutic drug monitoring (TDM). 
For many MKIs there is a clear relationship 
between exposure, toxicity and treatment efficacy 
(e.g. imatinib, pazopanib and sunitinib).98,100,107 
For some MKIs TDM could be an alternative 
way to manage DDIs in MKI therapy, where dose 
adjustments can be made if plasma levels are out-
side the therapeutic range. Furthermore, TDM 
has the advantage of monitoring MKI treatment, 
continuously over a longer time period which may 
result in better therapy efficacy. However, further 
research is needed to confirm the clinical rele-
vance of TDM as a tool in DDI management.
In conclusion, most MKIs are highly prone to 
cause DDIs. Drugs that elevate intragastric pH, 
strong inhibitors or inducers of CYP enzymes and 
drug transporters can result in clinically relevant 
changes in MKI exposure. For many DDIs the 
only evidence for a potential DDI comes from in 
vitro data or is predicted based on PBPK mode-
ling. Without clinical data it is difficult to deter-
mine the exact clinical relevance of these possible 
DDIs. In this review, we present practical recom-
mendations for management of MKI interactions 
in clinical practice. Acknowledging these DDIs 
by clinicians may eventually result in a more per-
sonalized and effective treatment with MKIs.
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